Robert E. Reiter, MD, MBA, Author at Grand Rounds in Urology

Robert E. Reiter, MD, MBA

Geffen School of Medicine at UCLA

Los Angeles, California

Robert E. Reiter, MD, MBA, is the Bing Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at the University of California, Los Angeles. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a $12 million research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. Dr. Reiter’s clinical interests include robotic surgical management of prostate cancer and the use of both MRI and molecular imaging tools to manage this disease. His research is focused on the development of novel antibodies for both treatment and imaging of prostate cancer, as well as on the role of epithelial to mesenchymal transition in castration and treatment resistance. Dr. Reiter completed his undergraduate studies at Yale University and earned his medical degree at Stanford University Medical School.

Disclosures:

Talks by Robert E. Reiter, MD, MBA

Molecular Imaging For Staging and Advanced Disease – Axumin and PSMA

Posted by Robert E. Reiter, MD, MBA | Jun 2020

Robert E. Reiter, MD, Bing Professor of Urology and Molecular Biology, Director of the Prostate Cancer Program, and Director of Urologic Research at the David Geffen School of Medicine at the University of California, Los Angeles, discusses the benefits of PSMA imaging in the context of biochemical recurrence. He reviews data from an Australian and an American study which both depict a positive correlation between PSA levels and PSMA prostate cancer detection rates, as well as high sensitivities for detection of recurrence based on pathologic confirmation. He then discusses the results of a study which compared PSMA with Axumin and found PSMA to be more than twice as effective in all areas but the prostate bed, which is most likely due to PSMA being excreted through the bladder. He argues that PSMA imaging can produce between a 29% and 76% change in prostate cancer management and allows for greater precision in treatment, resulting in fewer occurrences of unnecessary radiation therapy and long term systemic therapy.

Can MRI Be Used to Select Patients for Focal Therapy or To Guide Therapy?

Posted by Robert E. Reiter, MD, MBA | Jun 2019

Robert E. Reiter, MD, reviews data comparing tumor analysis as seen on MRI and fusion biopsy to whole-mount histology following radical prostatectomy. He discusses whether evidence supports the use of MRI for determining patient eligibility and planning for focal therapy.

PSMA Imaging: Beyond MRI in Prostate Cancer

Posted by Robert E. Reiter, MD, MBA | Oct 2018

Robert E. Reiter, MD, provides a brief update on the benefits of prostate-specific membrane antigen (PSMA) imaging for staging and detecting prostate cancer, as well as the emergence of PSMA imaging in the United States.

The Role of Molecular Imaging in Managing High Risk and Recurrent Prostate Cancer

Posted by Robert E. Reiter, MD, MBA | Apr 2018

Robert E. Reiter, MD, summarizes the impact advanced imaging techniques have had on staging and managing prostate cancer in the past few years. He discusses state-of-the-art molecular imaging, particularly focusing on prostate-specific membrane antigen (PSMA) targeted imaging.

The Ups and Downs of MRI Interrogation of the Gland

Posted by Robert E. Reiter, MD, MBA | Mar 2018

Robert Reiter, MD, discusses the uses of MRI in prostate cancer management, especially its ability to predict biochemical recurrence (BCR). He also explains the difference between mapping and targeted biopsies, and how MRI suspicion score and tumor volume are associated with grade, stage, and recurrence of disease.